2025 India Anti-Obesity Drugs Market Revenue Opportunities Report
Description
The 2025 India Anti-Obesity Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Indian anti-obesity drugs market are Novo Nordisk India Private Limited, Eli Lilly and Company (India) Pvt. Ltd., Pfizer India Inc., and GlaxoSmithKline Pharmaceuticals Limited. Novo Nordisk has pioneered the segment with the launch of its GLP-1 receptor agonist drug Wegovy (semaglutide 2.4 mg) in mid-2025, targeting weight management and cardiovascular risk reduction. Eli Lilly introduced its drug Mounjaro (tirzepatide) in India in March 2025, rapidly gaining traction with strong sales growth. Both companies are competing intensively, driving market expansion through innovation and aggressive marketing.
Pfizer India and GlaxoSmithKline also hold significant positions by leveraging their established pharmaceutical presence to distribute anti-obesity medications and invest in product development and partnerships. The market is growing rapidly due to increasing obesity rates, rising health awareness, and government support. These firms use strategies such as new drug approvals, partnerships, and patient-centric pricing to capitalize on India's expanding demand for effective anti-obesity treatment, particularly injectable GLP-1 receptor agonists that show superior efficacy.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Indian anti-obesity drugs market are Novo Nordisk India Private Limited, Eli Lilly and Company (India) Pvt. Ltd., Pfizer India Inc., and GlaxoSmithKline Pharmaceuticals Limited. Novo Nordisk has pioneered the segment with the launch of its GLP-1 receptor agonist drug Wegovy (semaglutide 2.4 mg) in mid-2025, targeting weight management and cardiovascular risk reduction. Eli Lilly introduced its drug Mounjaro (tirzepatide) in India in March 2025, rapidly gaining traction with strong sales growth. Both companies are competing intensively, driving market expansion through innovation and aggressive marketing.
Pfizer India and GlaxoSmithKline also hold significant positions by leveraging their established pharmaceutical presence to distribute anti-obesity medications and invest in product development and partnerships. The market is growing rapidly due to increasing obesity rates, rising health awareness, and government support. These firms use strategies such as new drug approvals, partnerships, and patient-centric pricing to capitalize on India's expanding demand for effective anti-obesity treatment, particularly injectable GLP-1 receptor agonists that show superior efficacy.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
